|
"coumar ms"的相关文件
显示项目 26-71 / 71 (共2页)
1 2 > >>
每页显示[10|25|50]项目
| 國家衛生研究院 |
2015-06-29 |
Homology modeling of DFG-in FMS-like tyrosine kinase 3 (FLT3) and structure-based virtual screening for inhibitor identification
|
Ke, YY;Singh, VK;Coumar, MS;Hsu, YC;Wang, WC;Song, JS;Chen, CH;Lin, WH;Wu, SH;Hsu, JT;Shih, C;Hsieh, HP |
| 國家衛生研究院 |
2015-04-14 |
Fused multicyclic compounds as protein kinase inhibitors
|
Hsieh, HP;Coumar, MS;Chao, YS |
| 國家衛生研究院 |
2015-01 |
Identification of ligand efficient, fragment-like hits from an HTS library: Structure-based virtual screening and docking investigations of 2H- and 3H-pyrazolo tautomers for Aurora kinase A selectivity
|
Sarvagalla, S;Singh, VK;Ke, YY;Shiao, HY;Lin, WH;Hsieh, HP;Hsu, JTA;Coumar, MS |
| 國家衛生研究院 |
2014-10-29 |
作為極光激酶抑制劑的稠合雙環嘧啶化合物
|
Hsieh, HP;Coumar, MS;Hsu, TA;Wu, SY;Chao, YS |
| 國家衛生研究院 |
2014-08 |
Ligand efficiency based approach for efficient virtual screening of compound libraries
|
Ke, YY;Coumar, MS;Shiao, HY;Wang, WC;Chen, CW;Song, JS;Chen, CH;Lin, WH;Wu, SH;Hsu, JT;Chang, CM;Hsieh, HP |
| 國家衛生研究院 |
2014-03-20 |
Fused bicyclic pyrimidine compounds as aurora kinase inhibitors
|
Hsieh, HP;Coumar, MS;Hsu, TA;Wu, SY;Chao, YS |
| 國家衛生研究院 |
2014-03 |
Efficient virtual screening using ligand efficiency based approach
|
Hsieh, HP;Ke, YY;Coumar, MS;Lin, WH;Wang, WC;Shiao, HY;Hsu, TAJ |
| 國家衛生研究院 |
2013-07-01 |
做為蛋白質激酶抑制劑之稠合多環化合物
|
Hsieh, HP;Coumar, MS;Chao, YS |
| 國家衛生研究院 |
2013-06-28 |
Optimization of ligand and lipophilic efficiency to identify an in vivo active furano-pyrimidine aurora kinase inhibitor
|
Shiao, HY;Coumar, MS;Chang, CW;Ke, YY;Chi, YH;Chu, CY;Sun, HY;Chen, CH;Lin, WH;Fung, KS;Kuo, PC;Huang, CT;Chang, KY;Lu, CT;Hsu, JT;Chen, CT;Jiaang, WT;Chao, YS;Hsieh, HP |
| 國家衛生研究院 |
2013-05 |
Aurora kinase inhibitors reveal mechanisms of HURP in nucleation of centrosomal and kinetochore microtubules
|
Wu, JM;Chen, CT;Coumar, MS;Lin, WH;Chen, ZJ;Hsu, JT;Peng, YH;Shiao, HY;Chu, CY;Wu, JS;Lin, CT;Chen, CP;Hsueh, CC;Chang, KY;Kao, LP;Huang, CY;Chao, YS;Wu, SY;Hsieh, HP;Chi, YH |
| 國家衛生研究院 |
2013-05 |
Protein kinase inhibitor design by targeting the Asp-Phe-Gly (DFG) motif: The role of the DFG motif in the design of epidermal growth factor receptor inhibitors
|
Peng, YH;Shiao, HY;Tu, CH;Liu, PM;Hsu, JT;Amancha, PK;Wu, JS;Coumar, MS;Chen, CH;Wang, SY;Lin, WH;Sun, HY;Chao, YS;Lyu, PC;Hsieh, HP;Wu, SY |
| 國家衛生研究院 |
2013-04-07 |
3D-QSAR assisted drug design: Identification of a potent quinazoline based Aurora kinase inhibitor
|
Ke, YY;Shiao, HY;Hsu, YC;Chang-Chu, Y;Wang, WC;Lee, YC;Lin, WH;Hsu, JTA;Chang, CW;Lin, CW;Yeh, TK;Chao, YS;Coumar, MS;Hsieh, HP |
| 國家衛生研究院 |
2013-02-11 |
作為酪胺酸激酶抑制劑之稠合雙環及多環嘧啶化合物
|
Hsieh, HP;Coumar, MS;Chao, YS;Hsu, TA;Lin, WH;Chen, YR |
| 國家衛生研究院 |
2013-01 |
3D-QSAR-assisted drug design: Identification of a potent quinazoline-based aurora kinase inhibitor
|
Ke, YY;Shiao, HY;Hsu, YC;Chu, CY;Wang, WC;Lee, YC;Lin, WH;Chen, CH;Hsu, JTA;Chang, CW;Lin, CW;Yeh, TK;Chao, YS;Coumar, MS;Hsieh, HP |
| 國家衛生研究院 |
2012-09 |
Anti-influenza drug discovery: Identification of an orally bioavailable quinoline derivative through activity- and property-guided lead optimization
|
Yeh, JY;Coumar, MS;Shiao, HY;Lin, TJ;Lee, YC;Hung, HC;Ko, S;Kuo, FM;Fang, MY;Huang, YL;Hsu, JT;Yeh, TK;Shih, SR;Chao, YS;Horng, JT;Hsieh, HP |
| 國家衛生研究院 |
2012-05-11 |
作為極光激酶抑制劑之稠合雙環嘧啶化合物
|
Hsieh, HP;Coumar, MS;Hsu, TA;Wu, SY;Chao, YS |
| 國家衛生研究院 |
2012-03-20 |
Fused bicyclic pyrimidine compounds as aurora kinase inhibitors
|
Hsieh, HP;Coumar, MS;Hsu, TA;Wu, SY;Chao, YS |
| 國家衛生研究院 |
2011-09-23 |
BPR1K653, a novel Aurora Kinase Inhibitor, exhibits potent anti-proliferative activity in P-gp170 (MDR1)-mediated VX680-resistant cancer cells in vitro and in vivo
|
Hsieh, HP;Cheung, CHA;Lin, WH;Hsu, TA;Coumar, MS;Chao, YS;Chang, JY |
| 國家衛生研究院 |
2011-08 |
BPR1K653, a novel aurora kinase inhibitor, exhibits potent anti-proliferative activity in MDR1 (P-gp170)-mediated multidrug-resistant cancer cells
|
Cheung, CH;Lin, WH;Hsu, TA;Hour, TC;Yeh, TK;Ko, S;Lien, TW;Coumar, MS;Liu, JF;Lai, WY;Shiao, HY;Lee, TR;Hsieh, HP;Chang, JY |
| 國家衛生研究院 |
2011-06 |
Aurora kinase inhibitor patents and agents in clinical testing: an update (2009-10)
|
Cheung, CHA;Coumar, MS;Chang, JY;Hsieh, HP |
| 國家衛生研究院 |
2011-04-28 |
Scaffold-hopping strategy: Synthesis and biological evaluation of 5,6-Fused bicyclic heteroaromatics to identify orally bioavailable anticancer agents
|
Tung, YS;Coumar, MS;Wu, YS;Shiao, HY;Chang, JY;Liou, JP;Shukla, P;Chang, CW;Chang, CY;Kuo, CC;Yeh, TK;Lin, CY;Wu, JS;Wu, SY;Liao, CC;Hsieh, HP |
| 國家衛生研究院 |
2010-12 |
Discovery of non-glycoside sodium-dependent glucose Co-transporter 2 (SGLT2) inhibitors by ligand-based virtual screening
|
Wu, JS;Peng, YH;Wu, JM;Hsieh, CJ;Wu, SH;Coumar, MS;Song, JS;Lee, JC;Tsai, CH;Chen, CT;Liu, YW;Chao, YS;Wu, SY |
| 國家衛生研究院 |
2010-10-28 |
Design and synthesis of tetrahydropyridothieno[2,3-d]pyrimidine scaffold based epidermal growth factor receptor (EGFR) kinase inhibitors: the role of side chain chirality and michael acceptor group for maximal potency
|
Wu, CH;Coumar, MS;Chu, CY;Lin, WH;Chen, YR;Chen, CT;Shiao, HY;Rafi, S;Wang, SY;Hsu, H;Chen, CH;Chang, CY;Chang, TY;Lien, TW;Fang, MY;Yeh, KC;Chen, CP;Yeh, TK;Hsieh, SH;Hsu, JT;Liao, CC;Chao, YS;Hsieh, HP |
| 國家衛生研究院 |
2010-10 |
Structural basis for the improved potency of peroxisome proliferator-activated receptor (PPAR) agonists
|
Peng, YH;Coumar, MS;Leou, JS;Wu, JS;Shiao, HY;Lin, CH;Lin, WH;Lien, TW;Chen, X;Hsu, JT;Chao, YS;Huang, CF;Lyu, PC;Hsieh, HP;Wu, SY |
| 國家衛生研究院 |
2010-08 |
Lead optimization of furanopyrimidine Aurora kinase inhibitors: Development of in vivo active agents in tumor xenograft models
|
Hsieh, HP;Chu, CY;Coumar, MS;Lin, WH;Chen, CT;Hsu, TA;Wu, SY;Chao, YS |
| 國家衛生研究院 |
2010-06-15 |
Fast-forwarding hit to lead: Aurora and epidermal growth factor receptor kinase inhibitor lead identification
|
Coumar, MS;Chu, CY;Lin, CW;Shiao, HY;Ho, YL;Reddy, R;Lin, WH;Chen, CH;Peng, YH;Leou, JS;Lien, TW;Huang, CT;Fang, MY;Wu, SH;Wu, JS;Chittimalla, SK;Song, JS;Hsu, JT;Wu, SY;Liao, CC;Chao, YS;Hsieh, HP |
| 國家衛生研究院 |
2010-02-25 |
Anti-influenza drug discovery: structure-activity relationship and mechanistic insight into novel angelicin derivatives
|
Yeh, JY;Coumar, MS;Horng, JT;Shiao, HY;Kuo, FM;Lee, HL;Chen, IC;Chang, CW;Tang, WF;Tseng, SN;Chen, CJ;Shih, SR;Hsu, JT;Liao, CC;Chao, YS;Hsieh, HP |
| 國家衛生研究院 |
2010-02-01 |
Identification, SAR studies, and X-ray Co-crystallographic analysis of a novel furanopyrimidine aurora kinase a inhibitor
|
Coumar, MS;Tsai, MT;Chu, CY;Uang, BJ;Lin, WH;Chang, CY;Chang, TY;Leou, JS;Teng, CH;Wu, JS;Fang, MY;Chen, CH;Hsu, JTA;Wu, SY;Chao, YS;Hsieh, HP |
| 國家衛生研究院 |
2009-08-13 |
Synthesis and evaluation of 3-aroylindoles as anticancer agents: Metabolite approach
|
Wu, YS;Coumar, MS;Chang, JY;Sun, HY;Kuo, FM;Kuo, CC;Chen, YJ;Chang, CY;Hsiao, CL;Liou, JP;Chen, CP;Yao, HT;Chiang, YK;Tan, UK;Chen, CT;Chu, CY;Wu, SY;Yeh, TK;Lin, CY;Hsieh, HP |
| 中國醫藥大學 |
2009-08 |
Synthesis and Evaluation of 3-Aroylindoles as Anticancer Agents: Metabolite Approach.
|
(Wu YS); (Coumar MS); (Chang JY); (Sun HY); (Kuo FM); (Kuo CC); (Chen YJ); (Chang CY); (Hsiao CL); (Liou JP); (Chen CP); 姚賢宗(Hsien-Tsung Yao); (Chiang YK); (Tan UK); (Chen CT); (Chu CY); (Wu SY); (Yeh TK); (Lin CY); (Hsieh HP)* |
| 國家衛生研究院 |
2009-07-23 |
Generation of ligand-based pharmacophore model and virtual screening for identification of novel tubulin inhibitors with potent anticancer activity
|
Chiang, YK;Kuo, CC;Wu, YS;Chen, CT;Coumar, MS;Wu, JS;Hsieh, HP;Chang, CY;Jseng, HY;Wu, MH;Leou, JS;Song, JS;Chang, JY;Lyu, PC;Chao, YS;Wu, SY |
| 國家衛生研究院 |
2009-07-03 |
Survivin counteracts the therapeutic effect of microtubule de-stabilizers by stabilizing tubulin polymers
|
Cheung, CH;Chen, HH;Kuo, CC;Chang, CY;Coumar, MS;Hsieh, HP;Chang, JY |
| 國家衛生研究院 |
2009-04-23 |
Design and structural analysis of novel pharmacophores for potent and selective peroxisome proliferator-activated receptor gamma agonists
|
Lin, CH;Peng, YH;Coumar, MS;Chittimalla, SK;Liao, CC;Lyn, PC;Huang, CC;Lien, TW;Lin, WH;Hsu, JT;Cheng, JH;Chen, X;Wu, JS;Chao, YS;Lee, HJ;Juo, CG;Wu, SY;Hsieh, HP |
| 國家衛生研究院 |
2009-04 |
Aurora kinase inhibitors in preclinical and clinical testing
|
Cheung, CH;Coumar, MS;Hsieh, HP;Chang, JY |
| 國家衛生研究院 |
2009-03 |
Advances in Aurora kinase inhibitor patents
|
Coumar, MS;Cheung, CHA;Chang, JY;Hsieh, HP |
| 國家衛生研究院 |
2009-03 |
Discovery and development of novel furano-pyrimidine analogs as Aurora kinase inhibitors
|
Hsieh, HP;Coumar, MS;Lin, CW;Reddy, GR;Tsai, MT;Lin, WH;Hsu, TA;Wu, SY |
| 國家衛生研究院 |
2009-02-26 |
Structure-based drug design of novel aurora kinase a inhibitors: Structural basis for potency and specificity
|
Coumar, MS;Leou, JS;Shukla, P;Wu, JS;Dixit, AK;Lin, WH;Chang, CY;Lien, TW;Tan, UK;Chen, CH;Hsu, JTA;Chao, YS;Wu, SY;Hsieh, HP |
| 國家衛生研究院 |
2008-12-25 |
Synthesis and structure-activity relationships of 2-amino-1-aroylnaphthalene and 2-hydroxy-1-aroylnaphthalenes as potent antitubulin agents
|
Reddy, GR;Kuo, CC;Tan, UK;Coumar, MS;Chang, CY;Chiang, YK;Lai, MJ;Yeh, JY;Wu, SY;Chang, JY;Liou, JP;Hsieh, HP |
| 國家衛生研究院 |
2008-06 |
Synthesis, beta-adrenergic receptor binding and antihypertensive potential of vanillin-derived phenoxypropanolamines
|
Coumar, MS; Jindal, DP; Bruni, G; Massarelli, P; Singh, R; Sharma, AK; Nandakumar, K; Bodhankar, SL |
| 國家衛生研究院 |
2008-03-01 |
Aurora kinase A inhibitors: Identification, SAR exploration and molecular modeling of 6,7-dihydro-4H-pyrazolo-[1,5-a]pyrrolo[3,4-d]pyrimidine-5,8-dione scaffold
|
Coumar, MS; Wu, JS; Leou, JS; Tan, UK; Chang, CY; Chang, TY; Lin, WH; Hsu, JTA; Chao, YS; Wu, SY; Hsieh, HP |
| 臺北醫學大學 |
2008 |
Synthesis and Structure-Activity Relationships of 2-Amino and 2-Hydroxy-1-Aroylnaphthalenes as Potent Antitubulin Agents
|
劉景平; Reddy GR; Kuo CC; Tan UK; Coumar MS; Chang CY; Lai MJ; Wu SY; Chang JY; Liou JP; Hsieh HP |
| 國家衛生研究院 |
2007-03-01 |
3-[2-((2S)-2-Cyano-pyrrolidin-1-yl)-2-oxo-ethylamino]-3-methyl-butyramide analogues as selective DPP-IV inhibitors for the treatment of type-II diabetes
|
Coumar, MS; Chang, CN; Chen, CT; Chen, X; Chien, CH; Tsai, TY; Cheng, JH; Wu, HY; Han, CH; Wu, SH; Huang, YW; Hsu, T; Hsu, LJ; Chao, YS; Hsieh, HP; Jiaang, WT |
| 國家衛生研究院 |
2006-09 |
MEDI 416-3- 2-((2S)-2-Cyano-pyrrolidin-1-yl)-2-oxo-ethylamino -3-methyl-butyr amide analogs as DPP-IV inhibitors for the treatment of type-II diabetes
|
Hsieh, HP;Coumar, MS;Chang, CN;Wu, SH;Chen, X;Chen, CT;Jiaang, WT |
| 國家衛生研究院 |
2006-06-15 |
Substituted pyrrolidine-2,4-dicarboxylic acid amides as potent dipeptidyl peptidase IV inhibitors
|
Tsai, TY; Coumar, MS; Hsu, T; Hsieh, HP; Chien, CH; Chen, CT; Chang, CN; Lo, YK; Wu, SH; Huang, CY; Huang, YW; Wang, MH; Wu, HY; Lee, HJ; Chen, X; Chao, YS; Jiaang, WT |
| 國家衛生研究院 |
2006-01-12 |
2-[3-[2-[(2S)-2-cyano-1-pyrrolidinyl]-2-oxoethylamino]-3-methyl-1-oxobutyl]-1,2,3,4-tetrahydroisoquinoline: A potent, selective, and orally bioavailable dipeptide-derived inhibitor of dipeptidyl peptidase IV
|
Tsu, H; Chen, X; Chen, CT; Lee, SJ; Chang, CN; Kao, KH; Coumar, MS; Yeh, YT; Chien, CH; Wang, HS; Lin, KT; Chang, YY; Wu, SH; Chen, YS; Lu, IL; Wu, SY; Tsai, TY; Chen, WC; Hsieh, HP; Chao, YS; Jiaang, WT |
| 國家衛生研究院 |
2005-03 |
Design, synthesis and sar of indole-based PPAR agonists
|
Hsieh, HP;Mahindroo, N;Coumar, MS;Wang, CC;Huang, CF;Lien, TW;Tsai, CH;Lin, YT;Lee, LH;Prakash, E;Hsu, TA;Chen, X;Wu, SY;Chen, CT;Chao, YS |
显示项目 26-71 / 71 (共2页)
1 2 > >>
每页显示[10|25|50]项目
|
